| Ident. | Authors (with country if any) | Title |
|---|
| 000271 |
Anne M. Landau [Danemark, Canada] ; M. Mallar Chakravarty [Danemark, Canada] ; Campbell M. Clark [Canada] ; Athanasios P. Zis [Canada] ; Doris J. Doudet [Danemark, Canada] | Electroconvulsive Therapy Alters Dopamine Signaling in the Striatum of Non-human Primates |
| 000430 |
Andrew R. Brown [Canada] ; BIN HU [Canada] ; Michael C. Antle [Canada] ; G. Campbell Teskey [Canada] | Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism |
| 000621 |
Daniel Levesque [Canada] ; Claude Rouillard [Canada] | Nur77 and retinoid X receptors : crucial factors in dopamine-related neuroadaptation |
| 000669 |
Manon Lebel [Canada] ; Pierre Robinson [Canada] ; Michel Cyr [Canada] | Canadian association of neurosciences review : The role of dopamine receptor function in neurodegenerative diseases |
| 000694 |
Pepijn Van Den Munckhof [Canada] ; Francois Gilbert [Canada] ; Michel Chamberland [Canada] ; Daniel Levesque [Canada] ; Jacques Drouin [Canada] | Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of parkinson's disease |
| 000847 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
| 000884 |
Naila Ismayilova [Canada] ; Alan Crossman [Canada] ; Alexei Verkhratsky [Canada] ; Jonathan Brotchie [Canada] | Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats |
| 000920 |
Pierre J. Blanchet [États-Unis, Canada] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] | Renaissance of amantadine in the treatment of Parkinson's disease |
| 000961 |
A. Jon Stoessl [Canada] ; Raul De La Fuente-Fernandez [Canada] | Dopamine receptors in Parkinson's disease: Imaging studies |
| 000984 |
Anette V. Nieves [Canada, États-Unis] ; Anthony E. Lang [Canada] | Treatment of excessive daytime sleepiness in patients with Parkinson's Disease with modafinil |
| 000988 |
J. Q. Lu [Canada] ; A. J. Stoessl [Canada] | Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats |
| 000A65 |
Pierre J. Blanchet [Canada] ; Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Daniel Levesque [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model |
| 000B33 |
Marco Scarselli [Italie] ; Marianna Armogida [Italie] ; Carla Pardini [Italie] ; Serena Chiacchio [Italie] ; Giovanni U. Corsini [Italie] | Apomorphine: A novel effect for an old compound |
| 000B35 |
Lana Depatie [Canada] ; Samarthji Lal [Canada] | Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? |
| 000B37 |
Kjell Fuxe [Suède] ; Ingrid Strömberg [Suède] ; Patrizia Popoli [Italie] ; Roberto Rimondini-Giorgini [Suède] ; Maria Torvinen [Suède] ; Sven O. Ögren [Suède] ; Rafael Franco [Espagne] ; Luigi F. Agnati [Italie] ; Sergi Ferre [Suède] | Adenosine receptors and Parkinson's disease: Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum |
| 000B57 |
E. F. Field [Canada] ; I. Q. Whishaw [Canada] ; S. M. Pellis [Canada] | Sex differences in catalepsy : evidence for hormone-dependent postural mechanisms in haloperidol-treated rats |
| 000B58 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
| 000B66 |
B. J. Snow [Canada] ; F. J. G. Vingerhoets [Canada] ; J. W. Langston [États-Unis] ; J. W. Tetrud [États-Unis] ; V. Sossi [Canada] ; D. B. Calne [Canada] | Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism |
| 000B70 |
P. E. Radau [États-Unis, Canada, Allemagne] ; R. Linke ; P. J. Slomka ; K. Tatsch | Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism |
| 000B95 |
J. M. Van Kampen [Canada] ; A. J. Stoessl [Canada] | Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia |
| 000B97 |
Frédéric Calon [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Pierre J. Blanchet [Canada] ; Marc Morissette [Canada] ; Richard Grondin [Canada] ; Martin Goulet [Canada] ; Jean-Pierre Doucet [Canada] ; George S. Robertson [Canada] ; Eric Nestler [États-Unis] ; Thérèse Di Paolo [Canada] ; Paul J. Bedard [Canada] | Dopamine-receptor stimulation : biobehavioral and biochemical consequences |
| 000C31 |
P. J. Blanchet [Canada] | Rationale for use of dopamine agonists in Parkinson's disease : Review of ergot derivatives |
| 000C57 |
G. Flores [Mexique, Canada] ; J. J. Liang [Mexique, Canada] ; A. Sierra [Mexique] ; D. Martinez-Fong [Mexique] ; R. Quirion [Mexique, Canada] ; J. Aceves [Mexique] ; L. K. Srivastava [Mexique] | Expression of dopamine receptors in the subthalamic nucleus of the rat : Characterization using reverse transcriptase-polymerase chain reaction and autoradiography |
| 000C59 |
T. A. Reader [Canada] ; K. M. Dewar [Canada] | Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum : implications for human Parkinson's disease |
| 000C60 |
V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys |
| 000D86 |
W. D. Hutchison [Canada] ; R. Levy [Canada] ; J. O. Dostrovsky [Canada] ; A. M. Lozano [Canada] ; A. E. Lang [Canada] | Effects of apomorphine on globus pallidus neurons in parkinsonian patients |
| 000E11 |
P. J. Blanchet [Canada] ; P. Allard [Canada] ; L. Gregoire [Canada] ; F. Tardif [Canada] ; P. J. Bedard [Canada] | Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients |
| 000E14 |
N. Galvez-Jimenez [Canada] ; A. E. Lang [Canada] | Perioperative problems in Parkinson's disease and their management : Apomorphine with rectal domperidone |
| 000E60 |
P. J. Blanchet ; B. Gomez-Mancilla [Canada] ; T. Di Paolo ; P. J. Bedard | Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia ? |
| 000F54 |
K. Mizukawa [Canada] ; E. G. Mcgeer ; P. L. Mcgeer | Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson disease, alzheimer disease, and neurologically normal controls |
| 000F70 |
H. A. Robertson [Canada] ; M. R. Peterson ; G. G. Worth | Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243 |
| 000F93 |
M. Guttman [Canada] | Dopamine receptors in Parkinson's disease |
| 001067 |
P. Seeman ; H. B. Niznik | Dopamine receptors and transporters in Parkinson's disease and schizophrenia |
| 001123 |
M. N. Hassan ; J. H. Thakar | Dopamine receptors in Parkinson's disease |
| 001146 |
A. E. Lang | Manipulating the dopaminergic system in Parkinson's disease |
| 001184 |
P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. Boucher | Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding |
